Medindia

X

'Microlyte Ag' Wound Dressing Gets Food and Drug Administration Clearance

by Dr. Trupti Shirole on  August 6, 2016 at 8:55 PM Research News   - G J E 4
The Food and Drug Administration (FDA) has given clearance to Imbed Biosciences to market its patented wound dressing for human use. The dressing it calls Microlyte Ag is a sheet as thin as Saran Wrap and can conform to the bumps and crevices of a wound, suggests company CEO Ankit Agarwal.
 'Microlyte Ag' Wound Dressing Gets Food and Drug Administration Clearance
'Microlyte Ag' Wound Dressing Gets Food and Drug Administration Clearance
Advertisement

The dressing is now cleared by the FDA as a class II medical device, for prescription and over-the-counter use.

‘The Food and Drug Administration (FDA) has given clearance to Imbed Biosciences to market its patented wound dressing for human use.’
Advertisement
Like many dressings now used to treat burns and other persistent wounds, Microlyte Ag contains silver to kill bacteria - but in much smaller quantities.

"Silver is an excellent antimicrobial agent," says Agarwal, a co-founder of the company in the Madison suburb of Fitchburg, "as it is active against a broad range of bacteria and yeast. But the large silver loads found in conventional silver dressings can be toxic to skin cells. Our dressing uses as little as 1% as much silver as the competition, and yet the tests we submitted to the FDA showed that Microlyte kills more than 99.99% of bacteria that it contacts."

That kill ratio even appeared in tests against some of the nastiest hospital-acquired superbugs, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus.

Microlyte overcomes a key problem with existing dressings: stiffness. Under a low-power microscope, a wound has bumps and fissures - hiding places for bacteria. The Microlyte dressing inherently adheres to moist surfaces and is so flexible that it drops into the fissures, leading to the sweet combination of greater destruction of bacteria at much lower doses of silver.

Microlyte has several other advantages, Agarwal says. It retains moisture yet is ultrathin and breathable, allowing oxygen to reach the wound and gases to exit, all factors that promote healing. The slow release of the silver means the dressing can remain in place for at least one day. And because the material is a hydrogel (a water-based gel), it can simply be rinsed off as needed before replacement.

Experience with animals shows that the ultra-thin dressing simply sloughs off as the wound heals. All of these advantages should reduce the need to change dressings, which can be so painful that sedation is needed, especially for children.

"Reducing or eliminating dressing changes reduces the pain that the patient experiences," says co-founder Michael Schurr, chair of general surgery at the Mountain Area Health Education Center in Asheville, North Carolina, and adjunct professor of surgery at the University of North Carolina. "It also reduces costs in supplies and reduces the burden to the health care system that supplies visiting nurses to do the dressing changes."

"We are seeing in a limited number of cases that it does provide us with a remarkable new tool for dealing with chronic wounds in dogs and cats treated at the UW-Madison School of Veterinary Medicine," says Jonathan McAnulty, chair of the Department of Surgical Sciences. "We certainly have no reason to think that this will be different with humans," adds McAnulty, who is also a company co-founder. "The principles are the same, and a lot of the problems are the same."

"The dramatic closure of wounds that have resisted months of conventional treatment suggests that chronic bacterial contamination of the wound surface, even when it looks relatively healthy, is a significant factor inhibiting healing in many cases," McAnulty says. "Once we treat with our dressing, we start to see very dramatic closure of these wounds."

McAnulty says he's starting to use Microlyte earlier in treatment. "Certainly it seems appropriate for prevention of infection as well as treatment."

The ultra-thin dressing material was invented in the lab of Nicholas Abbott, a UW-Madison professor of chemical and biological engineering, when Agarwal was a postdoctoral fellow and where he is now an honorary associate scientist.

The dressing will compete in the $2 billion market sector of "advanced wound dressings," which are used to treat diabetic ulcers, venous ulcers, burns, bedsores and other difficult wounds.

Source: Newswise
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All